Leadman(SZ:300289)2022-04-22 16:00Financial Performance - The company's revenue for Q1 2022 was CNY 191,578,138.79, representing a 65.55% increase compared to CNY 115,723,080.99 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 12,109,083.40, a 93.14% increase from CNY 6,269,691.46 year-on-year[3] - Basic and diluted earnings per share increased by 46.67% to CNY 0.022 from CNY 0.015 in the same period last year[3] - Net profit for Q1 2022 reached CNY 18,442,533.26, representing a 72.5% increase from CNY 10,683,942.73 in Q1 2021[27] - The total comprehensive income for the period was CNY 18,442,533.26, compared to CNY 10,683,942.73 in the previous period, representing an increase of approximately 72.5%[28] - The net profit attributable to the parent company was CNY 12,109,083.40, up from CNY 6,269,691.46, indicating a growth of about 93.5%[28] Cash Flow - The net cash flow from operating activities decreased by 71.75% to CNY 4,331,880.00, down from CNY 15,336,177.92 in the previous year[3] - Cash inflows from operating activities totaled CNY 248,793,538.36, compared to CNY 160,370,670.55 in the previous period, marking an increase of about 55%[30] - The net cash flow from operating activities was CNY 4,331,880.00, down from CNY 15,336,177.92, a decrease of approximately 71.7%[31] - Cash outflows from investment activities amounted to CNY 323,298,262.18, significantly higher than CNY 10,064,308.00 in the previous period[31] - The net cash flow from investment activities was negative at CNY -322,868,262.18, compared to CNY -9,887,308.00 previously[31] - The net cash flow from financing activities was CNY -4,452,419.68, a decrease from CNY -38,153,616.67 in the previous period, indicating an improvement[31] - The ending cash and cash equivalents balance was CNY 605,551,274.77, compared to CNY 319,826,863.94 at the end of the previous period, an increase of approximately 89.5%[32] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,338,149,870.85, a slight decrease of 0.44% from CNY 2,348,410,268.66 at the end of the previous year[3] - Total liabilities decreased to CNY 342,328,818.59 from CNY 370,301,842.38, indicating a reduction of approximately 7.6%[24] - The company's total equity attributable to shareholders increased by 0.66% to CNY 1,847,139,317.73 from CNY 1,835,030,234.33 at the end of the previous year[3] - The equity attributable to shareholders of the parent company increased to CNY 1,847,139,317.73 from CNY 1,835,030,234.33, reflecting a growth of 0.7%[25] Operating Costs and Expenses - The company reported a significant increase in operating costs, which rose by 123.72% to CNY 118,966,900.00 due to higher sales volumes[10] - Total operating costs for Q1 2022 were CNY 167,908,589.76, up 64.5% from CNY 101,996,186.58 year-on-year[26] - Research and development expenses for Q1 2022 were CNY 9,130,522.32, slightly down from CNY 9,259,306.78 in the previous year[26] - The company’s tax expenses rose by 68.20% to CNY 446,630.00, reflecting increased profits from its subsidiary[11] Business Development - The in vitro diagnostic reagent business generated revenue of 165.39 million RMB, accounting for 86.33% of total revenue, with a growth of 65.55% year-on-year[18] - The company obtained 8 new medical device registration certificates for in vitro diagnostic reagents during the reporting period[19] - The company launched 4 new biochemical diagnostic reagents and 5 new chemiluminescent diagnostic reagents[19] - The company received 1 invention patent and 2 utility model patents during the reporting period[20] - Other business income, mainly from property leasing, increased by 50.25% year-on-year to 7.56 million RMB, making up 3.95% of total revenue[18] Miscellaneous - The report for the first quarter was not audited[32]